title: Comparison of efficacy, safety, and tolerability of Neoral vs Sandimmun in de novo renal transplant patients over 24 months' treatment.
authors.affiliation: Sandoz AG, Nürnberg.
authors.forename: D
authors.initials: D
authors.lastname: Abendroth
authors.forename: B
authors.initials: B
authors.lastname: Buchholz
authors.forename: W
authors.initials: W
authors.lastname: Land
authors.forename: G
authors.initials: G
authors.lastname: May
authors.forename: M
authors.initials: M
authors.lastname: Wiesel
authors.forename: L
authors.initials: L
authors.lastname: Färber
authors.forename: A
authors.initials: A
authors.lastname: Korn
authors.forename: A
authors.initials: A
authors.lastname: Maibücher
mesh_terms: D000284:Administration, Oral; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005858:Germany; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D013997:Time Factors; D014508:Urea / Q000097:blood; D014527:Uric Acid / Q000097:blood
chemical_list: D007166:Immunosuppressive Agents; D014527:Uric Acid; D016572:Cyclosporine; D014508:Urea; D003404:Creatinine